FDA mifepristone review stretches into 2027 as debate continues
The FDA says its ongoing safety review of mifepristone will continue into next year, keeping one of the nation’s most closely watched drug-policy fights in motion.
FDA review of abortion pill safety will stretch into 2027
The FDA says its safety review of mifepristone will continue into next year, keeping attention on a drug that is widely used for abortion and miscarriage care.